Key points are not available for this paper at this time.
Results Evaluation Program, when it was organized in 1956 under the sponsorship of the National Cancer Institute, was to provide a base line for measuring progress.2 With this end i n mind, participation in the program was limited to institutions with tumor registries that had been functioning for some time. Thus, we now have a large body of data concerning the survival of patients with breast cancer from 1940 on. It is appropriate to begin this discussion with a review of what we now know about the survival of the women who were treated some 25 years ago. There are, of course, a variety of measures of the efficacy of treatment, but survival time is a basic index.
Cutler et al. (Mon,) studied this question.